RTOG Foundation Study 3503

Study Date: October 15, 2019 | Status:  Completed

Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Principal Investigator

Manmeet Ahluwalia, MD

Primary Objective

To determine the efficacy of TTFields Therapy with bevacizumab as measured by the overall survival rate at 6 months from the time of registration.

Patient Population

Confirmation of recurrence or progression on contract MRI of histologically proven GBM or other grade IV malignant glioma.

Participating Sites

Institution NameCityState/Country
Emory University, Winship Cancer InstituteAtlantaGA
Froedert and Medical College of WisconsinMenomonee FallsWI
Medical University of South CarolinaCharlestonSC
University of California San Diego Moores Cancer CenterLa JollaCA
University of Florida Health Cancer CenterOrlandoFL
University of California Irvine, Chao Family Comprehensive Cancer CenterOrangeCA
University of RochesterRochesterNY
Washington University School of MedicineSt. LouisMO